Diego Villa, MD, FRCPC, elaborated on the progress made with bendamustine and rituximab as induction therapy for transplant eligible and ineligible patients with mantle cell lymphoma.
Diego Villa, MD, FRCPC
Advertisement
Articles by Diego Villa, MD, FRCPC
Advertisement
Latest Updated Articles
Diego Villa, MD, FRCPC, Discusses Bendamustine and Rituximab as Induction Therapy in MCLPublished: January 3rd 2020 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
How Can Oncology Staffing Shortages Be Remedied?
2
Lifileucel Confers Durable Responses in Pretreated Advanced NSCLC Type
3
Glofitamab/Polatuzumab Vedotin Exhibits Response Durability in R/R LBCL
4
Atezolizumab Combo Elicits No Significant Benefit in Ovarian Cancer
5
